Cervical Cancer Elimination: A Global Imperative
A high-level panel is calling for renewed efforts to meet the World Health Organization (WHO) Global Strategy’s 2030 targets – and eliminate cervical cancer by 2050 worldwide. Despite being preventable and curable with early detection, cervical cancer remains the fourth most common cancer and a leading cause of cancer death among women globally.
The Challenge: A Disproportionate Burden
Currently, approximately 340,000 women die annually from cervical cancer, with the vast majority of these deaths occurring in low-income countries. This disparity highlights cervical cancer as a stark reflection of global health inequity. In Guyana, for example, cervical cancer is the second leading cause of cancer deaths among women, and in some countries, it is the primary cause. Around 600,000 women are diagnosed annually, representing 6.5% of new cancer cases and 7.7% of cancer deaths, with 94% of deaths occurring in developing nations.
The 2030 Targets and the Path to Elimination
The WHO’s strategy aims for elimination through achieving specific targets by 2030: 90% HPV vaccination coverage, 70% screening coverage, and 90% treatment of detected pre-cancerous lesions. Meeting these targets is crucial for putting countries on track to reduce cervical cancer incidence to less than 4 cases per 100,000 women by 2050.
Although developed countries are largely on course to meet the 2030 goals, developing nations face a significantly longer trajectory. At current rates of progress, many will not achieve elimination until 2120. Success stories, such as Rwanda, demonstrate that these targets are attainable with strong political will and effective implementation.
Key Areas for Improvement
Several key areas require focused attention to accelerate progress towards elimination:
Expanding HPV Vaccination
Increasing HPV vaccination coverage is paramount. School-based vaccination programs are proving effective, but challenges remain in addressing misinformation and establishing robust systems for delivery. Gender-neutral vaccination strategies can further improve coverage and overcome barriers.
Shifting to HPV Testing
Transitioning from traditional Pap smears to HPV testing is crucial, particularly in low- and middle-income countries. HPV testing is more accurate and cost-effective in identifying high-risk cases. The implementation of self-sampling methods and accessible laboratory services is similarly essential.
Improving Access to Treatment
Ensuring access to effective treatment for pre-cancerous lesions is vital. This includes expanding access to thermal ablation and other treatment modalities, particularly in rural and underserved communities. Mobile screening clinics and task-shifting to community health workers can help bridge the gap in access.
Addressing the HPV 35 Genotype
Recent research indicates that the HPV 35 genotype is increasingly prevalent in Africa and is not covered by current HPV vaccines. This poses a significant challenge to elimination efforts in the region. Further research and the development of vaccines that include HPV 35 are urgently needed. A recent review of the burden of HPV 35 in African Cervical Pathologies indicates prevalence rates from 19-30% in Mozambique, 22-26% in Kenya, 17% in South Africa and 11% in Zimbabwe and Tanzania.
Global Collaboration and Political Will
Eliminating cervical cancer requires sustained global collaboration and increased political will. International partnerships, such as those facilitated by the Center for Global Health Development and Inclusion (CeHDI) and the WHO, are essential for driving progress. Gavi, the Vaccine Alliance, has approved the inclusion of improved vaccines covering more genotypes as they become available.
As Guyana’s ambassador, Leslie Ramsammy, stated, “The question is no longer whether cervical cancer can be eliminated, but when and whether the world will mobilize the political will and resources needed to ensure that no woman dies from a preventable disease.”
Looking Ahead
The global community has the tools and knowledge to eliminate cervical cancer. By prioritizing vaccination, screening, treatment, and addressing emerging challenges like the HPV 35 genotype, we can move closer to a future where cervical cancer is no longer a threat to women’s health. Just as international collaboration eradicated smallpox, a concerted global effort can end cervical cancer by 2050.